Keryx Biopharmaceuticals to Present at The Oppenheimer & Co. Inc. 23rd Annual Healthcare Conference

Keryx Biopharmaceuticals to Present at The Oppenheimer & Co. Inc. 23rd Annual
                            Healthcare Conference

Presentation Scheduled for Thursday, December 13th at 3:55pm ET

PR Newswire

NEW YORK, Dec. 10, 2012

NEW YORK, Dec. 10, 2012 /PRNewswire/ --Keryx Biopharmaceuticals, Inc.
(Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting at the Oppenheimer & Co. Inc. 23rd Annual
Healthcare Conference, being held December 12-13, 2012, in New York City. Mr.
Bentsur's presentation is scheduled to take place on Thursday, December 13,
2012 at 3:55pm Eastern Time.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the
Investor Information page of the Company's Website at
http://investors.keryx.com. An archived version of the webcast will be
available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticalsis focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for
the treatment of hyperphosphatemia (elevated phosphate levels) in patients
with end-stage renal disease is being conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2
development for the management of phosphorus and iron deficiency in anemic
patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.
Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Website: http://www.keryx.com